FLEMINGTON, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (AMEX: NVD), today announced that Par Pharmaceuticals has been granted sublicense rights for the development and commercialization of Zensana™ (ondansetron HCl, oral spray). Ondansetron is a 5-HT3 antagonist to prevent nausea and vomiting after chemotherapy, radiation and surgery. Upon successful development and approval, the Company believes Zensana™ could be among the first in its class to be available in an oral spray form. Par and NovaDel anticipate collaborating on the development of a formulation of Zensana™, with Par responsible for updating the New Drug Application and commercializing the product in North America.
